Abstract
Job cuts are ahead for Merck & Co. The drug company has approved a restructuring program meant to streamline its manufacturing and supply network and reduce its global real estate footprint. The company says the program will cost $800 million to $1.2 billion to implement; some 55% of the costs will be cash outlays for employee severance and facility shutdowns. The rest will be noncash expenses such as accelerated depreciation. The company anticipates completing the program by the end of 2023. It expects charges of $500 million this year, $187 million of which were in the first quarter.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
